Conditions: Advanced Breast Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 100
Healthy volunteers: no

Brief summary:
The purpose of this study is to find out what effect the combination of fulvestrant (Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant alone.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Dasatinib intervention 2: Fulvestrant
Intervention descriptions: intervention 1: Tablets, Oral, 100 mg, once daily (QD), upto 2 years intervention 2: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years

Protocol document: